PP
STOK icon

PDT Partners’s Stoke Therapeutics STOK Stock Holding History

PDT Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,942
Closed -$154K – 848
2024
Q4 		$154K Sell
13,942
-42
-0.3% -$516 0.01% 674
2024
Q3 		$172K Sell
13,984
-55
-0.4% -$779 0.02% 668
2024
Q2 		$190K Sell
14,039
-7,387
-34% -$99.7K 0.02% 615
2024
Q1 		$289K Buy
+21,426
New +$130K 0.03% 538
2023
Q3 		– Sell
-23,592
Closed -$251K – 680
2023
Q2 		$251K Sell
23,592
-12,244
-34% -$130K 0.03% 483
2023
Q1 		$299K Sell
35,836
-4,626
-11% -$41.7K 0.04% 463
2022
Q4 		$373K Buy
40,462
+24,851
+159% +$258K 0.06% 444
2022
Q3 		$200K Sell
15,611
-8,059
-34% -$128K 0.03% 720
2022
Q2 		$313K Buy
+23,670
New +$360K 0.03% 732
2021
Q3 		– Sell
-25,554
Closed -$860K – 906
2021
Q2 		$860K Buy
25,554
+18,897
+284% +$668K 0.06% 404
2021
Q1 		$259K Buy
+6,657
New +$379K 0.02% 650

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PDT Partners's STOK Position: Q1 2025 in Review

PDT Partners sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 13,942 shares — an estimated $154K sold.

PDT Partners first reported a position in STOK in Q1 2021 and held it in 11 quarters. The position peaked at $860K in Q2 2021. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

  • PDT Partners reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 13,942 Stoke Therapeutics shares in Q1 2025, an estimated $154K.
  • PDT Partners first reported a position in Stoke Therapeutics in Q1 2021 and held it in 11 quarters.
  • PDT Partners's Stoke Therapeutics position peaked at $860K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.